There are a number of assistance programs available to help your patients obtain their medication, if they qualify. To find the program that best meets their needs, we have created ASSIST, your Access Solutions and Support Team. Now, there is one number to call to get answers to questions regarding how your patients can obtain their medications and supplies.
One Number for All Product Access Needs: 1-877-UNITHER (1-877-864-8437)
At 1-877-UNITHER (1-877-864-8437), our ASSIST Advisors will talk with your office staff, or directly with your patients, to help resolve issues and manage cases until completion.
All patients can utilize the ASSIST Program:
- Patients with insurance
Patients with either private or governmental insurance coverage may qualify for one of the available co-pay assistance options.
-
Patients without insurance
We may be able to help obtain medication and supplies for eligible patients who cannot afford therapy, are not adequately insured, or are close to the lifetime limit of their current insurance policy.*
-
Patients with interrupted coverage
We may be able to assist eligible patients in obtaining continued medication coverage, at a reasonable cost or no cost at all, if they experience a temporary interruption of therapy caused by a gap in their insurance coverage.*
By calling 1-877-UNITHER (1-877-864-8437), our ASSIST Advisors can also help verify insurance benefits, assist with submissions of prior authorization documentation, provide guidance for pharmacy claim denials and appeals, collaborate with Specialty Pharmacy Service Providers, and much more.
ASSIST your patients with financial solutions and support.
*Patients must meet certain eligibility criteria to qualify for assistance.
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms
associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic
or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic
indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who
are intolerant of the subcutaneous route, or in whom these risks are considered warranted.
In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical
deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
Important Safety Information for Remodulin
- Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk
of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
- Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH. Remodulin is a potent pulmonary and systemic
vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet
aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. Remodulin dosage adjustment may be
necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care.
Therapy with Remodulin may be used for prolonged periods, and the patient’s ability to administer Remodulin and care for an infusion system should
be carefully considered.
- Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic
effects or for unacceptable infusion site symptoms.
- Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided. Caution
should be used in patients with hepatic or renal insufficiency.
- The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and
infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment
with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising,
and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation, and edema.
For more information about REMODULIN, please see the Full Prescribing Information.
Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).